Needham & Company LLC Reiterates “Buy” Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “buy” rating restated by Needham & Company LLC in a note issued to investors on Tuesday, Benzinga reports. They currently have a $12.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target indicates a potential upside of 135.29% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

BioCryst Pharmaceuticals Stock Down 3.0 %

NASDAQ BCRX opened at $5.10 on Tuesday. The stock has a market capitalization of $1.05 billion, a PE ratio of -4.77 and a beta of 1.96. The company has a 50 day moving average price of $4.89 and a two-hundred day moving average price of $5.45. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. BioCryst Pharmaceuticals’s revenue was up 34.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.28) earnings per share. As a group, equities analysts anticipate that BioCryst Pharmaceuticals will post -0.69 EPS for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of BCRX. China Universal Asset Management Co. Ltd. increased its position in BioCryst Pharmaceuticals by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 2,388 shares during the period. Teacher Retirement System of Texas increased its position in BioCryst Pharmaceuticals by 4.9% during the third quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 2,519 shares during the period. Fifth Third Bancorp increased its position in BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,500 shares during the period. ProShare Advisors LLC increased its position in BioCryst Pharmaceuticals by 9.1% during the first quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 4,041 shares during the period. Finally, Teza Capital Management LLC increased its position in BioCryst Pharmaceuticals by 12.8% during the third quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company’s stock worth $261,000 after acquiring an additional 4,180 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.